Coronary CT angiography has long shown strong diagnostic value, but software that turns scans into quantitative plaque measurements was held back by payment. That barrier is easing, and cardiac imaging AI companies are raising capital to capture the opportunity.
On September 2, 2026, Boston-based Elucid announced a $55 million oversubscribed Series D, bringing total funding to about $185 million. The round included a large medtech company joining as Elucid's fourth publicly traded strategic investor, along with IAG Capital Partners and Elevage Medical Technologies, a platform created by Patient Square Capital.
